Vaccine immunopotentiators of the future

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 6, 2007, Pages 750-755

  Schijns, V E J C ^a   Degen, W G J ^a  

^a INTERVET INTERNATIONAL BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM SALT; CPG 1826; FREUND ADJUVANT; IMMUNOLOGICAL ADJUVANT; LIGAND; LIPID A; LIQUID PARAFFIN; MONOCLONAL ANTIBODY CD28; NANOPARTICLE; OLIGONUCLEOTIDE; OVALBUMIN; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 7 LIGAND; TOLL LIKE RECEPTOR 8 LIGAND; TROMETAMOL; UNCLASSIFIED DRUG; VACCINE; WATER; WATER OIL CREAM;

ANTIBODY TITER; DRUG DESIGN; DRUG FORMULATION; DRUG SAFETY; EMULSION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPOTENTIATION; IMMUNOREACTIVITY; MICROBIAL IMMUNITY; NONHUMAN; PERFORMANCE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VETERINARY MEDICINE;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM COMPOUNDS; ANIMALS; DRUG DESIGN; DRUG SYNERGISM; EMULSIONS; FORECASTING; HUMANS; NANOPARTICLES; VACCINES;

EID: 36148980080     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100394     Document Type: Review

References (30)

1. Le Moignic, P. Les vaccins en emulsion dans les corps gras ou "lipo-vaccins". Comptes Rendus de la Societe de Biologie. 79, 201-203 (1916).
2. Freund, J., Cascals, J. & Hosmer, E.P. Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Proc. Soc. Exp. Biol. Med. 37, 509-513 (1937).
3. Glenny, A.T., Pope, C., Waddington, H. & Wallace, U. The antigenic value of toxoid precipitated by potassium alum. J. Pathol. Bacteriol. 29, 28-45 (1926).
4. Janeway, C.A. Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today 13, 11-16 (1992).
5. Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085-2088 (1998).
6. Banchereau, J. & Steinman, R.M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
7. Rogers, K.A., DeKrey, G.K., Mbow, M.L., Gillespie, R.D., Brodskyn, C.I. & Titus, R.G. Type 1 and type 2 responses to Leishmania major. FEMS Microbiol. Lett. 209, 1-7 (2002).
8. Nossal, G. A healthier climate for the funding of vaccine research. Nat. Immunol. 5, 457-459 (2004).
9. Scott, P., Artis, D., Uzonna, J. & Zaph, C. The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development. Immunol. Rev. 201, 318-338 (2004).
10. Schijns, V.E.J.C. Induction and direction of immune responses by vaccine adjuvants. Crit. Rev. Immunol. 21, 75-85 (2001).
11. Schijns, V.E.J.C. Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol. 12, 456-463 (2000).
12. Zinkernagel, R.M., Ehl, S., Aichele, P., Oehen, S., Kundig, T. & Hengartner, H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol. Rev. 156, 199-209 (1997).
13. Herbert, W.J. Antigenicity of soluble protein in the presence of high levels of antibody: a possible mode of action of the antigen adjuvants. Nature 210, 747-748 (1966).
14. Herbert, W.J. The mode of action of mineral-oil emulsion adjuvants on antibody production in mice. Immunology 14, 301-318 (1968).
15. Holm, B.C., Svelander, L., Bucht, A. & Lorentzen, J.C. The arthritogenic adjuvant squalene does not accumulate in joints, but gives rise to pathogenic cells in both draining and non-draining lymph nodes. Clin. Exp. Immunol. 127, 430-435 (2002).
16. Janeway, C.A. Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harbor Symp. Quant. Biol. 54, 1-13 (1989).
17. Matzinger, P. Tolerance, danger and the extended family. Ann. Rev. Immunol. 12, 991-1045 (1994).
18. Chabalgoity, J.A., Baz, A., Rial, A. & Grille, S. The relevance of cytokines for development of protective immunity and rational design of vaccines. Cytokine Growth Factor Rev. 18, 195-207 (2007).
19. Kalinski, P., Hilkens, C.M., Wieringa, E.A. & Kapsenberg, M.L. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today 20, 561-567 (1999).
20. Gavin, A.L. et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314, 1936-1938 (2006).
21. Wickelgren, I. Mouse studies question importance of toll-like receptors to vaccines. Science 314, 1859-1860 (2006).
22. O'Hagan, D.T. & Valiante, N.M. Recent advances in the discovery and delivery of vaccines and adjuvants. Nat. Rev. Drug Discov. 2, 727-735 (2003).
23. Guy, B. The prefect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 5, 505-517 (2007).
24. Welters, M.J. et al. Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. Vaccine 25, 1379-1389 (2007).
25. Takeda, K., Kaisho, T. & Akira, S. Toll-like receptors. Annu. Rev. Immunol. 21, 335-376 (2003).
26. Chakraborty, M., Schlom, J. & Hodge, J.W. The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses. Cancer Immunol. Immunother. 56, 1471-1484 (2007).
27. Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006).
28. Kapadia, D. & Fong, L. CTLA-4 blockade: autoimmunity as treatment. J. Clin. Oncol. 23, 8926-8928 (2005).
29. Berner, V. et al. IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat. Med. 13, 354-360 (2007).
30. Schijns, V.E.J.C. & O'Hagan, D. Immunopotentiators in Modern Vaccines (Academic; Elsevier, Amsterdam, 2006).